{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:29:58Z","timestamp":1786480198428,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"name":"Fondo Nacional de Recursos"},{"name":"Fondo de Investigaci\u00f3n en Nefrolog\u00eda"},{"DOI":"10.13039\/100009891","name":"International Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,9]]},"abstract":"\n Background<\/jats:title>\n Optimal immunosuppressive treatment for membranous nephropathy is still a matter of controversy. Current recommendations include oral cyclophosphamide combined with steroids (modified Ponticelli regimen) as first-line treatment in patients who are high risk. However, concerns about the cumulative toxicity of oral cyclophosphamide persist. In the last 30 years, a protocol based on low-dose intravenous cyclophosphamide plus steroids has been used to treat membranous nephropathy in Uruguay. We aimed to assess the efficacy of this regimen to induce clinical remission in patients with membranous nephropathy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this retrospective, observational cohort study, we analyzed the outcome of 55 patients with membranous nephropathy treated between 1990 and 2017 with a 6-month course of alternating steroids (months 1, 3, and 5) plus intravenous cyclophosphamide (single dose of 15 mg\/kg on the first day of months 2, 4, and 6).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At 24 months, 39 (71%) patients achieved clinical response with complete remission observed in 23 patients (42%) and partial remission in 16 (29%). Median time to achieve partial and complete remission was 5.9 and 11.5 months, respectively. Absence of response was observed in 16 patients (29%), five of whom started chronic RRT after a median follow-up of 3.5 years. Clinical relapse occurred in nine of 33 (27%) patients at a median of 34 months after treatment discontinuation.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Replacement of oral cyclophosphamide with a single intravenous pulse on months 2, 4, and 6 of the modified Ponticelli regimen can be an effective and safe alternative for treatment of membranous nephropathy.<\/jats:p>\n <\/jats:sec>\n \n Podcast<\/jats:title>\n This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/K360\/2020_09_24_KID0002802020.mp3<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0002802020","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T14:34:38Z","timestamp":1596810878000},"page":"943-949","source":"Crossref","is-referenced-by-count":21,"title":["Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy"],"prefix":"10.34067","volume":"1","author":[{"given":"Leonella","family":"Luzardo","sequence":"first","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Ottati","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"},{"name":"Department of Nephrology, Military Hospital, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Trujillo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital 12 October, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela","family":"Garau","sequence":"additional","affiliation":[{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"},{"name":"Department of Quantitative Methods, School of Medicine, University of the Republic, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Gonz\u00e1lez Bedat","sequence":"additional","affiliation":[{"name":"Department of Nephrology, CASMU, Montevideo, Uruguay"},{"name":"Uruguayan Dialysis Registry, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Coiti\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda H.","family":"Aunchayna","sequence":"additional","affiliation":[{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"},{"name":"Department of Pathology, Clinic Hospital, School of Medicine, University of the Republic, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Santiago","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Department of Nephrology, M\u00e9dica Uruguaya, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Baldovinos","sequence":"additional","affiliation":[{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Silvari\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"},{"name":"Department of Nephrology, COSEM, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ferreiro","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Department of Nephrology, CASMU, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Gadola","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"},{"name":"Department of Nephrology, CASMU, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Noboa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hena","family":"Caorsi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinic Hospital, University of the Republic, Montevideo, Uruguay"},{"name":"Uruguayan Registry of Glomerulopathies, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: When and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.04321007","article-title":"Idiopathic membranous nephropathy: Diagnosis and treatment","volume":"3","author":"Fervenza","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000368589","article-title":"Rituximab in primary membranous nephropathy: First-line therapy, why not?","volume":"128","author":"Cravedi","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","article-title":"Does cyclophosphamide still play a role in glomerular diseases?","volume":"17","author":"Ponticelli","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"B11-20230821","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000481635","article-title":"Membranous nephropathy: Approaches to treatment","volume":"47","author":"Bomback","year":"2018","journal-title":"Am J Nephrol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfr371","article-title":"Management of patients with membranous nephropathy","volume":"27","author":"Hofstra","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"Suppl 1","key":"B14-20230821","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1093\/ndt\/gfw404","article-title":"Membranous nephropathy: Thinking through the therapeutic options","volume":"32","author":"Cattran","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"e0206637","DOI":"10.1371\/journal.pone.0206637","article-title":"Temporal trends in biopsy proven glomerular disease in Uruguay, 1990\u20132014","volume":"13","author":"Garau","year":"2018","journal-title":"PLoS One"},{"key":"B18-20230821","first-page":"113","article-title":"[Frequency of diagnosis and clinic presentation of glomerulopathies in Uruguay]","volume":"25","author":"Mazzuchi","year":"2005","journal-title":"Nefrologia"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: Quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230821","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European vasculitis study group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1797.2010.01427.x","article-title":"Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: A single centre\u2019s retrospective study","volume":"16","author":"Yuan","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ckj\/sfw152","article-title":"Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy","volume":"10","author":"Mathrani","year":"2017","journal-title":"Clin Kidney J"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nep.12955","article-title":"Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy","volume":"23","author":"Kanigicherla","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-116-6-438","article-title":"Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone","volume":"116","author":"Falk","year":"1992","journal-title":"Ann Intern Med"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-121-5-199409010-00003","article-title":"Preserving renal function in patients with membranous nephropathy: Daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide","volume":"121","author":"Reichert","year":"1994","journal-title":"Ann Intern Med"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: Definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","article-title":"Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy","volume":"33","author":"Laluck","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2215\/CJN.10240819","article-title":"Management of membranous nephropathy after MENTOR","volume":"15","author":"Trivin-Avillach","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002802020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:09Z","timestamp":1786478229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002802020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0002802020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}